Cytokinetics
CYTK
138 hedge funds and large institutions have $324M invested in Cytokinetics in 2019 Q1 according to their latest regulatory filings, with 16 funds opening new positions, 63 increasing their positions, 25 reducing their positions, and 14 closing their positions.
152% more repeat investments, than reductions
Existing positions increased: 63 | Existing positions reduced: 25
50% more funds holding in top 10
Funds holding in top 10: 2 → 3 (+1)
39% more call options, than puts
Call options by funds: $607K | Put options by funds: $436K
29% more capital invested
Capital invested by funds: $251M → $324M (+$72.8M)
14% more first-time investments, than exits
New positions opened: 16 | Existing positions closed: 14
1% more funds holding
Funds holding: 137 → 138 (+1)
0.28% more ownership
Funds ownership: 72.66% → 72.94% (+0.28%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FCMI
Foresite Capital Management IV
Larkspur,
California
|
+$11.4M |
| 2 |
Millennium Management
New York
|
+$6.5M |
| 3 |
OM
Opaleye Management
Boston,
Massachusetts
|
+$6.25M |
| 4 |
WA
Wasatch Advisors
Salt Lake City,
Utah
|
+$5.38M |
| 5 |
Two Sigma Investments
New York
|
+$2.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
-$20.1M |
| 2 |
LPU
Lansdowne Partners (UK)
London,
United Kingdom
|
-$8.74M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$4.86M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$2.56M |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
-$1.24M |
CYTK Hedge Fund Activity: Q1 2019 in Review
138 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Cytokinetics (CYTK) for Q1 2019, worth a combined $324M — up 29% from $251M a quarter earlier.
Buyers outnumbered sellers: 16 funds opened new CYTK positions and 14 closed out — a net gain of 2 holders — while 63 added to existing stakes and 25 trimmed.
The largest buyer was Foresite Capital Management IV, adding an estimated $11.4M. The largest seller was Great Point Partners, exiting entirely with an estimated $20.1M sold.
- 138 institutional investors held Cytokinetics (CYTK) as of Q1 2019, up from 137 in Q4 2018.
- Funds reported $324M of Cytokinetics stock for Q1 2019, up 29% quarter-over-quarter.
- 16 funds opened new Cytokinetics positions in Q1 2019 and 14 closed out, a net change of +2 holders.
- The largest Cytokinetics buyer in Q1 2019 was Foresite Capital Management IV, an estimated $11.4M added.
- The largest Cytokinetics seller in Q1 2019 was Great Point Partners, an estimated $20.1M sold.
Based on aggregated 13F filings for Q1 2019.